Pfizer Inc
-
Open
34.08
-
Previous Close
34.06
-
Volume (Avg)
30.05M (21.72M)
-
Day's Range
33.97-34.22
-
52Wk Range
29.83-37.39
-
Market Cap.
203.92B
-
Dividend Rate (Yield)
1.28 (3.75%)
-
Beta
1.03
-
Shares Outstanding
5.97B
-
P/E Ratio (EPS)
28.74 (1.19)
Top Stories
-
UPDATE: Pfizer (PFE) gets CRL on Epoetin Alfa Biosimilar
StreetInsider 2 days agoPfizer Inc. (NYSE: PFE) today announced that it has received a Complete Response Letter (CRL) from the United States (U.S.) Food and Drug Administration (FDA) regarding the company’s Biologics License Application (BLA) for its proposed epoetin alfa ...
-
Pfizer Declares 32-Cent Third-Quarter 2017 Dividend
NASDAQ -
Pfizer: Buy Shares On Price Weakness
Seeking Alpha -
Pfizer To Lose Exclusivity Of Key Brands
Seeking Alpha -
Traders take bullish position on Pfizer
NASDAQ 4 days agoOption traders are taking bullish positions Pfizer ( PFE) Wednesday. Both the Jily 35 and July 37.50 calls have traded in very high volume today. The 37.50 has only one trade, but that trade was 22,500 contracts against no open interest. Since the contract ...
-
Pfizer Downgraded To 3 Stars By Vetr Crowd
Benzinga -
Drug medication list
Madison County Courier -
The Baldwin Brothers Inc. MA Cuts Stake in Pfizer, Inc. (PFE)
healthcaremenu.net -
Lilly, Pfizer get boost for non-opioid pain drug
Indianapolis Business Journal -
Being a Vaccine Heretic in the Church of Big Pharma
americaoutloud.com -
Pfizer Biosimilar Delayed By FDA Warning Letter
Law 360 -
Pfizer Wins Immediate Appeal Over Unsettled Whistleblower Questions
thelegalintelligencer.com -
Pfizer scientists devise 2-pronged attack against blood cancers
Fierce Biotech -
Pharmalittle: Pfizer biosimilar rejected again by FDA; families battle insurers over Sarepta drug
www.statnews.com -
STAT Plus: Pharmalittle: Pfizer biosimilar rejected again by FDA; families battle insurers over Sarepta drug
bioportfolio.com 1 day agoPfizer is a global pharmaceutical company, the largest in world based on annual sales. In 2009, annual sales were worth $45,448m. Pfizer spend £550m on R&D in the UK alone, and have colleagues in 180 countries. Lipitor, one of its produ... Biosimilars or ...
-
US FDA rejects Pfizer's Epogen biosimilar citing McPherson site warning
in-Pharma -
Pfizer gets CRL on Epogen biosimilar from FDA
processandproduction.pharmaceutical-business-review.com -
Global Sulfasalazine Market 2017: Cadila, IPCA, Zydus, Pfizer and Icn Pharmaceuticals
Medgadget
